Auranofin

Excreted Unchanged %
50
Half-Life (Normalesrd) Hours
70-80 days/No data
Plasma Protein Binding %
60
Volume Of Distribution L/Kg
No data
Dose For Normal Renal Function
6 mg q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
50% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
Avoid [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
Avoid [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None
Supplement For Dialysis [Recommendation Level]: Pd
PD: None
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Avoid, [D]
References
Chaffman M, Brogden RN, Heel RC, Speight TM, Avery GS. Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis. Drugs. 1984; 27: 378-424. [PMID: 6426923]
Toxicity Notes
Proteinuria and nephrotic syndrome.